Alternatives to levodopa in the initial treatment of early Parkinson's disease

Drugs and Aging

Volumn 22, Issue 9, 2005, Pages 731-740

  Lees, Andrew ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMPHETAMINE; APOMORPHINE; BENZATROPINE; BN 82451; BROMOCRIPTINE; CABERGOLINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LAZABEMIDE; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; NONERGOLINE; OLANZAPINE; ORPHENADRINE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; PROCYCLIDINE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SAFINAMIDE; SELEGILINE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AGING; ANKLE EDEMA; ANTICHOLINERGIC EFFECT; AUTONOMIC DYSFUNCTION; BRAIN DISEASE; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTINUOUS INFUSION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; EDEMA; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; LIVEDO RETICULARIS; LUNG DISEASE; MICTURITION DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NEUROTOXICITY; NIGHTMARE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PSYCHOSIS; RETROPERITONEAL FIBROSIS; REVIEW; SOMNOLENCE; TACHYPHYLAXIS; VALVULAR HEART DISEASE; VOMITING;

AGED; AGED, 80 AND OVER; AMANTADINE; ANTIPARKINSON AGENTS; DOPAMINE AGENTS; DOPAMINE AGONISTS; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; MUSCARINIC ANTAGONISTS; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 24144502098     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200522090-00002     Document Type: Review

References (61)

1. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54: 363-75
2. Abbott RD, Ross GW, White LR, et al. Environmental, lifestyle, and physical precursors of clinical Parkinson's disease: recent findings from the Honolulu-Asia Aging Study. J Neurol 2003; 250 Suppl. 3: III30-9
3. Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease [published erratum appears in CMAJ 2003; 168: 544]. CMAJ 2003; 168: 293-301
4. Strickland D, Bertoni JM. Parkinson's prevalence estimated by a state registry. Mov Disord 2004; 19: 318-23
5. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001; 18: 389-96
6. Olanow CW. The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 2004; 55: 41-60
7. Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson's disease therapy. Ann Neurol 2003; 53 Suppl. 3: S3-12
8. LeWitt PA, Nyholm D. New developments in levodopa therapy. Neurology 2004; 62: S9-16
9. Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 2005; 20 Suppl. 11: S3-10
10. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41: 261-309
11. Movement Disorders Society Evidence-Based Review. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17: S1-S166
12. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998; 50: S17-25
13. Pfeiffer RF. Potential of transdermal drug delivery in Parkinson's disease. Drugs Aging 2002; 19: 561-70
14. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial [published erratum appears in Arch Neurol. 2005; 62: 430]. Arch Neurol 2004; 61: 1044-53
15. Romrell J, Fernandez HH, Okun MS. Rationale for current therapies in Parkinson's disease. Expert Opin Pharmacother 2003; 4: 1747-61
16. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-98
17. Chan DK. The art of treating Parkinson disease in the older patient. Aust Fam Physician 2003; 32: 927-31
18. MacMahon DG. The initial drug treatment of older patients with Parkinson's disease: consider an agonist, but don't demonise dopa. Age Ageing 2003; 32: 244-5
19. Hristova AH, Koller WC. Early Parkinson's disease: what is the best approach to treatment. Drugs Aging 2000; 17: 165-81
20. Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs Aging 2003; 20: 847-55
21. Navan P, Findley LJ, Jeffs JA, et al. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor. Mov Disord 2003; 18: 1324-31
22. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002; 17: 1235-41
23. Watts RL, Wendt J, Nausieda PL, et al. Efficacy, safety, and tolerability of the rotigotine transdermal patch in patients with early-stage, idiopathic Parkinson's disease: a multicenter, multinational, randomized, double-blind, placebo-controlled trial [abstract]. Mov Disord 2004; 19: 258
24. Bhatia K, Brooks DJ, Burn DJ, et al. Updated guidelines for the management of Parkinson's disease. Hosp Med 2001; 62: 456-70
25. Agarwal P, Fahn S, Frucht SJ. Diagnosis and management of pergolide-induced fibrosis. Mov Disord 2004; 19: 699-704
26. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-83
27. Rascol O, Pathak A, Bagheri H, et al. New concerns about old drugs: valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord 2004; 19: 611-3
28. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the RE-AL-PET study. Ann Neurol 2003; 54: 93-101
29. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284: 1931-8
30. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61
31. Lees AJ, Katzenschlager R, Head J, et al. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001; 57: 1687-94
32. Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004; 25: 215-21
33. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol 2003; 53 Suppl. 3: S87-97
34. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-71
35. Myllyla VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline as initial treatment in de novo parkinsonian patients. Neurology 1992; 42: 339-43
36. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients: Swedish Parkinson Study Group. Neurology 1998; 51: 520-5
37. Waters CH, Sethi KD, Hauser RA, et al. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 2004; 19: 426-32
38. Montastruc JL, Chaumerliac C, Desboeuf K, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol 2000; 23: 271-5
39. Churchyard A, Mathias CJ, Boonkongchuen P, et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 228-34
40. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa: Parkinson Study Group. Ann Neurol 1996; 39: 37-45
41. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease: Parkinson's Disease Research Group of the United Kingdom. BMJ 1995; 311: 1602-7
42. Ives N, Stowe R, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 2004; 329: 593-6
43. Ben-Shlomo Y, Bhatia K. Using monoamine oxidase type B inhibitors in Parkinson's disease. BMJ 2004; 329: 581-2
44. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56: S1-S88
45. Clarke A, Johnson ES, Mallard N, et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J Neural Transm 2003; 110: 1257-71
46. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561-6
47. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-43
48. Parkinson Study Group, Stern M. A controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO Study) [abstract]. Ann Neurol 2003; 54:S27
49. Rascol O, Brooks D, Melamed E, et al. A comparative randomised study of rasagiline versus placebo or entacapone as adjunct to levodopa in Parkinson's disease patients with motor fluctuations (the LARGO Study) [abstract]. Neurology 2004; 62: 346
50. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-8
51. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double blind, parallel-group trial. Lancet 2005; 365: 947-54
52. Am OB, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004; 355: 169-72
53. Maruyama W, Takahashi T, Youdim M, et al. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SHSY5Y cells. J Neural Transm 2002; 109: 467-81
54. Effect of lazabemide on the progression of disability in early Parkinson's disease: the Parkinson Study Group. Ann Neurol 1996; 40: 99-107
55. Safinamide: FCE 26743, NW 1015, PNU 151774, PNU 151774E. Drugs R D 2004; 5: 355-8
56. Klivenyi P, Ferrante RJ, Gardian G, et al. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease [published erratum appears in J Neurochem 2003; 87: 272]. J Neurochem 2003; 86: 267-72
57. Lees AJ. Drugs for Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 607-10
58. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996; 46: 1551-6
59. Katzenschlager R, Sampaio C, Costa J, et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003; (2): CD003735
60. Emre M. Dementia in Parkinson's disease: cause and treatment. Curr Opin Neurol 2004; 17: 399-404
61. Hughes AJ, Daniel SE, Blankson S, et al. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-8